Focus: AskBio is a 5,000+ employee biotechnology company headquartered in Durham, NC, specializing in cellular and protein-based therapies with a focus on gene therapy for rare genetic and neurodegenerative diseases. Founded in 2020, the company operates as a mid-cap biotech with a robust early-stage pipeline across multiple therapeutic areas.
Profile data last refreshed 14h ago · AI intelligence enriched 19h ago
Cooling — net -6 jobs in 30d
7 added, 13 removed. Slower than typical.
Best for scientists and clinicians comfortable with early-stage gene therapy risk and execution timelines, seeking deep technical ownership in a scaling biotech with real pipeline momentum.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AskBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AskBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Front-Line Sac-TMT Shows Benefit in PD-L1-Positive Lung Cancer as Chinese Regulators Mull Approval - Precision Medicine Online
Front-Line Sac-TMT Shows Benefit in PD-L1-Positive Lung Cancer as Chinese Regulators Mull Approval Precision Medicine Online
European Biotechs Developing Next-Generation Cell and Gene Therapy Manufacturing Technologies - PharmTech.com
European Biotechs Developing Next-Generation Cell and Gene Therapy Manufacturing Technologies PharmTech.com
Bayer to buy eye-drug developer Perfuse Therapeutics for up to $2.45 billion - MSN
Bayer to buy eye-drug developer Perfuse Therapeutics for up to $2.45 billion MSN
AskBio Doses First Patient in Phase 1/2 Gene Therapy Trial for Late-Onset Pompe Disease - BioPharm International
AskBio Doses First Patient in Phase 1/2 Gene Therapy Trial for Late-Onset Pompe Disease BioPharm International
Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline - BioPharma Dive
Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline BioPharma Dive
Bayer is acquiring eye disease drug developer Perfuse Therapeutics for up to $2.45 billion - qz.com
Bayer is acquiring eye disease drug developer Perfuse Therapeutics for up to $2.45 billion qz.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo